Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dapagliflozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 0.87 |
| ▸ | SLC5A1 | P13866 | 14/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapagliflozin SCHEMBL13259899 | 0.93 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL13445694 | 0.89 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL3683145 | 0.89 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13445659 | 0.88 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL13445677 | 0.87 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13445681 | 0.87 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL13259912 | 0.86 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13445684 | 0.84 | SLC5A2 (0.76) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL3683074 | 0.84 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL13259906 | 0.84 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A4 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.